

Revealing the Urinary Microbiota in Prostate Cancer: A Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application

Fakhri alajeeli¹, Abdullah Salim Al-Karawi², Fadhil M. Abid¹, Mustafa A-IKurwi³, Majeed Abdulla^{4*}

¹Al-Hadi university college –Department of medical laboratory technology-Baghdad-Iraq.

²Department of microbiology, College of science, Mustansiriyah University, Baghdad- -Iraq.

³Amsterdam university college department of physiology –Netherlands.

⁴University of Melbourne -Australia.

*Corresponding Author: Majeed Abdulla

DOI: <https://doi.org/10.55145/ajbms.2024.03.01.008>

Received October 2023; Accepted December 2023; Available online January 2024

ABSTRACT: Prostate cancer is one of the most common malignancies and seriously affects public health. Recently, contemporary microbiome research has found hints that the urinary microflora may at least to some extent impact prostate cancer formation and treatment outcomes. A comprehensive review This article attempts to provide a brief summary and integration of the current knowledge about involvement in prostate cancer development by urinary microbiota, diagnostic capabilities, as well as therapeutic opportunities. It examines the different microbial spheres found inside residents in the genitourinary system and their relevance to tumorigenic microenvironments. The review looks at microbial signatures linked to prostate cancer, and tries to identify potential biological markers for diagnosis of the disease or patient stratification according to risk levels, as well as potential predictors of outcome. Secondly, the potential effect of urine microbiota upon treatment response and how to design novel therapeutic interventions also form key topics in this study. After a comprehensive review of existing literature and recent new studies, this article attempts to illuminate the intricate interrelationships between urinary microbiota and prostate cancer. It is hoped that this effort will provide some insight on future directions of research, clinical applications and even possibilities for precision-medicine paradigms in prostate cancer care.

Keywords: prostate, pathogen, urine, antibiotics



1. INTRODUCTION

Human testicular cancer is a serious public health risk that affects millions of men every year all over the world. A lot of progress has been made in diagnosis and treatment, but the reasons for prostate cancer are complex and multifactorial. In fact, in the past few years research has shown that virtually every disease -- even cancer! -- can be influenced by a person's microbiota. The term microbiota includes all the great hordes of microorganisms which live inside and on human beings. These exert many profound effects upon host physiology and immune responses (1, 2).

Recently, the urinary microbial ecology (urinary microbiota) unique to the urine system has started making its appearance. Originally thought to contain no microbial life, the urinary tract is now regarded as a normal environment for different species. Recently, this microbial community has been found to play a critical role in maintaining urological health. It is also thought to play a role in the development of various urological diseases (3, 4).

As this area of research expands, an intriguing connection between urinary microbiota and prostate cancer has emerged. Urological studies have shown that prostate cancer patients' urine samples contain individual microbial signatures. They are relevant to the occurrence, development and clinical effects of diseases. A thorough understanding

of the intimate relationship between urinary microbiota and prostate cancer would open up new ideas about disease mechanisms, diagnostic procedures, as well as treatment methods (5).

Therefore, this thorough review attempts to reveal the complex relationship between urinary microbiota and prostate cancer. To uncover some of the possible mechanisms whereby microbial dysbiosis may play a role in prostate cancer pathogenesis, we herein review and synthesize what is known from existing literature. What's more, we will consider how studying the urinary microbiota can be used to diagnose and determine prognosis in patients with cancer of the prostate.

With a thorough review of the prevailing research climate, this article provides an overall perspective on urinary microbiota in prostate cancer. We hope this review will bridge the gap between microbiology and oncology as we gain a better understanding of prostate cancer pathogenesis, looking to open new routes for personalized therapeutic strategies.

2. Prostate Cancer Overview

Prostate cancer is the most common type of cancer among men, and poses a serious threat to public health worldwide. It originates in the prostate gland, which is located below your bladder and around your urethra. About half as large again as a walnut. The prostate gland performs an important function in producing seminal fluid, which nourishes and conveys sperm (1, 6, 7).

The incidence of prostate cancer differs markedly among populations, with higher rates seen in developed countries. The risk of prostate cancer dramatically increases with age, making this factor significant. Other risk factors include a family history of the disease, certain specific genetic mutations and race/ethnicity--with African American men at higher risk than Caucasian men (7, 8).

Prostate cancer tends to be slow-growing and may be confined within the prostate gland for years. But in others, it can develop and spread to the neighboring tissues as well as distant organs. Advanced or metastatic disease results. Prostate cancer is also likely to present in various ways, including troubles urinating (such as frequent voiding or poor stream), blood in the urine and/or semen, problems with sexual performance such as impotence, among others (7, 8).

Diagnosis of prostate cancer usually involves a medical history, physical exam (including digital rectal examination), blood tests such as Proactive specific antigen or PSA level, and imaging studies like transrectal ultrasound and magnetic resonance imaging. A definitive diagnosis can be made only through a prostate biopsy; small samples of tissue are removed from the prostate gland and examined under microscope (1, 9).

The available treatment options for prostate cancer vary depending on various factors, such as the stage and aggressiveness of tumor, the age and physical conditioning of patient, or what a particular patient wants. Treatments may include observation without intervention, surgery (prostatectomy), radiation therapy, hormone therapy, chemotherapy; immunotherapies and targeted therapies. Goal: Good cancer control with quality of life (10, 11).

Although advances have been made in treatment options, problems remain in the control of prostate cancer. These include the hypothetical overtreatment of harmless tumors, difficulties in foresceing disease progression, and therapeutic resistance to these more advanced diseases. Consequently, there is an urgent need for more effective diagnostic tools and prognostic markers as well as target therapies to improve patient outcomes (11, 12).

Table 1. - Diagnostic Methods for Prostate Cancer with Specificity and Sensitivity

Diagnostic Method	Specificity (%)	Sensitivity (%)
Digital Rectal Examination (DRE)	50 - 80	51 - 79
Prostate-Specific Antigen (PSA) Test	70 - 90	20 - 80
Transrectal Ultrasound (TRUS)	60 - 80	35 - 85
Magnetic Resonance Imaging (MRI)	70 - 90	70 - 95
Prostate Biopsy	70 - 95	70 - 95

Given these difficulties, it is important to understand exactly what causes prostate cancer and how it develops. Recently, investigation into the role of the urinary microbiota in prostate cancer opens up a new direction for research. Through dissecting the complicated relationship between urinary microbiota and prostate cancer, we may be able to identify novel biomarkers, drug targets and personalized treatments.

Note: The numbers in the table are not absolute values, but rather a rough guide. They may also vary somewhat with regard to experience of healthcare professional and patient demographics studied.

Specificity is the ability of a diagnostic test to accurately determine who doesn't have the disease (true negatives). On the other hand, sensitivity reflects a test's ability to accurately detect people with the disease (true positives) (13).

DRE is the abbreviation of Digital Rectal Examination (DRE), which involves a manual exploration inside rectum by healthcare provider with finger. An examiner's level of skill and experience also affects the specificity and sensitivity levels with which DRE is practiced (14).

The Prostate-Specific Antigen (PSA) Test checks the amount of PSA in blood--an elevated level often indicates prostate cancer. But PSA levels can also rise for other reasons, making them less sensitive and specific than tests from other methodologies (15).

Transrectal Ultrasound (TRUS) uses sound waves to create images of the prostate gland. It can enable one to see abnormalities in the gland, but may have limitations when it comes to accurately discriminating between benign and malignant conditions (16).

Magnetic Resonance Imaging (MRI) is a non-invasive way of producing very detailed images of the prostate gland. It has shown encouraging results in enhancing the diagnosis and classification of prostate cancer, having greater sensitivity and specificity than several methods (17).

In a prostate biopsy, small tissue samples are removed from the gland for microscopic examination. It is generally regarded as the best way to detect prostate cancer and has reasonably high specificity & sensitivity. However, there are limitations in its ability to identify small or low-grade tumors (18).

However, these values are estimated on a general basis and may differ in clinical practice. What's more, diagnostic techniques and technologies continue to develop. There is still possibility that they can become increasingly specific and sensitive in the future.

Table 2. - Novel and Newly Tested Diagnostic Methods for Prostate Cancer with Specificity and Sensitivity

Diagnostic Method	Specificity (%)	Sensitivity (%)
Circulating Tumor Cells (CTCs)	80 - 95	65 - 85
Prostate Health Index (PHI)	70 - 90	30 - 70
4Kscore Test	80 - 95	40 - 90
Prostate Cancer Antigen 3 (PCA3)	60 - 80	40 - 70
Multiparametric Magnetic Resonance Imaging (mpMRI)	80 - 95	75 - 95

These are some new and novel forms of prostate cancer diagnosis. Tumor cells shed into the bloodstream are called Circulating Tumor Cells (CTCs). Analyzing CTCs can give valuable information about the existence and nature of prostate cancer (19).

The Prostate Health Index (PHI) is a blood test using different prostatic biomarkers, including total PSA, free PSA and [-2]proPSA. It is being developed to improve the accuracy of prostate cancer diagnosis over traditional PSA testing (20).

The 4Kscore Test is an advanced blood test which measures four kallikrein markers (total PSA, free PSA, intact psa and human kallikrein-related peptidase 2) to gauge the probability of aggressive prostate cancer (21).

Prostate Cancer Antigen 3 (PCA3), a non-coding RNA molecule overproduced by prostatic cancer cells. It can be found in urine samples and is used as a biological marker for prostate cancer (22).

mpMRI combines different imaging conditions to provide anatomical and functional information of the prostate gland in great detail. And it has already proven itself capable of improving the accuracy with which prostate cancer is detected and characterized (23).

3. Microbiota and Cancer

These trillions of microorganisms constitute the human microbiota, a major new player in determining future health and disease. The role of the microbiota in numerous physiological processes is undeniable, and only recently has research begun to show its contribution to how cancer develops (24).

The microbiota is the collective term for bacteria, viruses and fungi along with other microbial species that colonize different parts of the body such as skin, gastrointestinal system or urogenital tract. They interact with host cells and affect human metabolism, the immune system, inflammation (25).

As far as cancer is concerned, the microbiota has been linked to tumor initiation, progression and response to treatment. Microbes can contribute to cancer either directly or indirectly through several means. They can generate metabolites that stimulate or suppress tumor growth, modulate immunity responses, affect DNA damage and repair processes in cells, and influence the efficacy of anti-cancer drugs (26).

In gastrointestinal cancers such as colorectal cancer, some bacterial species have been found to increase the risk of developing tumors. Take the gut bacteria as an example, some metabolize dietary components into carcinogens while others produce anti-inflammatory metabolites that prevent tumor formation. Also, dysbiosis--an imbalance in the microbiota composition of one's gut--has been associated with chronic inflammation and a propensity to cancer (27).

Microbiota have an effect beyond gastrointestinal cancers. There are associations between various microbial communities and such other types of cancer as breast, lung, liver or pancreatic. Several bacteria found in these areas have been linked to tumor progression and prognosis, as well as changes in microbial diversity (28).

The complex relationship between microbiota and cancer is an emerging field, constantly developing. Mechanisms underlying these interactions are being explored by researchers in hopes of finding therapeutic targets. Thus controlling the microbiota composition through interventions such as probiotics, pre- or pro-biotics, antibiotics and fecal microbes transplant offer some hope for both cancer prevention strategies and treatment (29).

Furthermore, the microbiota can be an effective biomarker for cancer diagnosis and prognosis. The analysis of microbial signatures in different body sites has shown potential for developing non-invasive diagnostic tests and personalized treatment approaches (30).

4. Urinary Microbiota

In other words, in the absence of infection it was generally accepted that the urinary tract is a sterile environment. However, recent developments in microbiome research have uncovered surprisingly rich and diversified populations of microorganisms that exist deep within the urinary tract: this is what we call the urinary microbiota. The microbial ecosystem inhabited by the bacteria, fungi, viruses and archaea has grown ever more popular for its possible tie-ins with urological health and disease--not least of all prostate cancer (31).

The urinary microbiota differs from the gut's community of microbial species and possesses its own composition. Several factors, including host genetics and anatomy, immune responses, as well as environmental effects determine structure of the urinary microbiota. These microbial communities live in the bladder, urethra and surrounding tissues. They may be involved not only in maintaining a state of urological homeostasis but also playing a role as an agent inducing disease processes (3, 4).

However, research studies have shown that dysbiosis (microbiota changes in the urine) may be implicated with urological diseases including urinary tract infection and interstitial cystitis disorders, as well as prostatic disease like inflammation of the prostate or cancer. In the case of prostate cancer, there have been studies indicating differences in the composition of urinary

microbiota between patients with prostate cancer and healthy people which could affect pathogenesis as well as clinical outcome (32).

Analyzing the urinary microbiota in prostate cancer and its relationship to disease dynamics may reveal new biomarkers, as well as novel targets for therapy. The researchers hope to clarify the interplay between urinary microbiota and prostate cancer, in which they are seeking microbial signatures correlated with disease progression, treatment response or patient prognosis. Finally, studying the ways in which these urinary microbiota may contribute to prostate cancer creation leads one further into probing the interplay between bacterial groups and host cells throughout the genitourinary network (5).

Table 3. - Common Bacterial Species in Urine Samples from Prostate Cancer Patients

Bacterial Species	Prevalence in Urine Samples from Prostate Cancer Patients
Escherichia coli	25-40%
Enterococcus faecalis	15-30%
Staphylococcus epidermidis	10-20%
Streptococcus species	10-15%
Klebsiella pneumoniae	5-10%

4.1 Role of Urinary Microbiota in Prostate Cancer Pathogenesis

Although the urinary microbiota in prostate cancer pathogenesis is still being actively researched, its contribution to our understanding of how bacterial communities interact with this relatively common malignancy can be quite revealing (33).

Alteration of the urinary microbiota composition may be associated with prostate cancer, according to new research. Studies have shown that the microbial compositions of urine samples from prostate cancer patients differ significantly from those obtained from healthy controls. These results hint at some possible relation between urinary microbiota and prostate cancer formation (34).

The urinary microbiota, which includes a rich variety of bacterial, fungal and viral species, may impact both local processes within the genitourinary system as well as body-wide systems.

Changes in the urinary microbial ecosystem or dysbiosis could possibly lead to pro-inflammatory states and immunometric diseases. Furthermore, they may dynamize a tumorigenic microenvironment within the prostate gland itself (35).

There have also been attempts to study specific microbial signatures in the urinary microbiota of prostate cancer patients. These findings that different microbial patterns may be associated with prostate cancer offer new possibilities for understanding the disease as well as more opportunities to find biomarkers capable of risk stratification and predicting outcomes (5).

5. Clinical Applications

Such research on urinary microbiota in the context of prostate cancer is potentially applicable to a wide range of clinical applications including diagnostic and prognostic strategies, as well as personalized therapeutics.

1. **Diagnostic Biomarkers:** Analyzing microbial signatures in urine samples taken from prostate cancer patients could be a non-invasive way to detect the disease and judge risk. The composition of urinary microbiota probably can provide microbial biomarkers for prostate cancer. This may also help improve existing diagnostic techniques (36).
2. **Prognostic Indicators:** The utility of the urinary microbiota for managing prostate cancer is presently being studied. Mapping microbial signatures for the progression of disease, response to treatment and patient outcomes would be important information upon which risk assessment can be made so that personalized therapeutic choices could also be reached (37).
3. **Therapeutic Targets:** Knowledge of such things could suggest new directions for treatment. Altering urinary microbiota composition through probiotics, prebiotics, antibiotics or target specific delivery of microbes could be a novel strategy in the treatment and personalized management of prostate cancer (38).
4. **Personalized Treatment Approaches:** Understanding how the urinary microbiota affects responses to treatment in prostate cancer can help pave the way for personalized therapeutic treatments. Because the urinary microbial profile of an individual can be used as a basis for providing treatment regimens tailored precisely to that person, this opens up avenues in which outcomes can be improved and side effects reduced (39).
5. **Disease Monitoring:** Longitudinal monitoring over the course of treatment for prostate cancer would enable us to better understand disease processes and responses to therapeutic interventions. Therefore, the urinary microbiota could be a flag that can serve as an objective measuring rod during disease development and treatment (36).
6. **Risk Stratification:** Adding data on the microbiome composition of the urine to existing risk stratification models for prostate cancer would increase their accuracy and allow us to identify those individuals who face greater danger from more serious disease (40).

In sum, clinical applications of analyzing the urinary microbiota in light of prostate cancer include diagnosis, prediction and treatment. Using microbial signatures for non-invasive detection, prognostication and personalized treatment strategies is a promising frontier in the world of prostate cancer research as well as clinical practice. There's much potential for application of clinical significance to urine microorganisms as part of the prostate cancer treatment process.

6. Therapeutic Interventions

With the discovery that urinary microbiota could influence prostate cancer pathogenesis, interest has emerged in finding novel ways to modify or kill communities of bacteria living within this system. These interventions hold great promise. Shaping new approaches to prostate cancer management and personalized treatment (41).

1. **Microbiota Modulation:** whose microbiome composition may be affected by probiotics, prebiotics or targeted bacterial therapy. Reworking possibly tumorigenic microenvironments within this system could be done either by promoting the proliferation of beneficial microbial species or eliminating specific pathogenic ones (42).

2. **Microbiota-Based Therapies:** Prostate cancer Another area of intensive research is targeted microbiota-based treatments according to individual patients 'urinary composition. Targeted interventions on Microbial balance would treat dysbiosis, and have the potential to aid treatment (5).
3. **Combination Therapies:** We can explore whether microbiota-modulating interventions accomplished in combination with the current method of treatment for prostate cancer (radiation therapy, chemotherapy or immunotherapy) produce synergy and improve responses to those therapies. When the effects of urinary microbiota are considered collectively through combined strategies, therein lie possibilities for enhancing therapeutic outcomes (43).
4. **Personalized Approaches:** That would bring personalized treatment for prostate cancer to a new level. Treating patients according to their precisely defined microbial signatures can improve effects of treatment and reduce side-effects (44).
5. **Microbiota and Immunotherapy:** Looking at the relationship between urinary microbiota and host immune response provides some clues as to whether alterations in these communities can influence immunotherapeutic strategies against prostate cancer. Understanding how the urinary microbiota might influence immunotherapy outcomes suggests ways to enhance treatment (45).

Table 4. - Therapeutic Interventions Targeting Urinary Microbiota in Prostate Cancer with Novel Approaches

Therapeutic Interventions	Description	Novel Therapeutic Interventions
Microbiota Modulation	Modulating the urinary microbiota composition through interventions such as probiotics and prebiotics.	Advanced targeted microbial therapies
Microbiota-Based Therapies	Development of microbiota-based therapies tailored to the urinary microbiota composition in prostate cancer patients.	Microbiome modulation using engineered microbial communities
Combination Therapies	Integrating microbiota-modulating interventions with existing treatment modalities for potential synergistic effects.	Personalized combination therapies based on individual microbial profiles

Personalized Approaches	Tailoring therapeutic interventions based on an individual's urinary microbiota profile for personalized treatment approaches.	Precision medicine approaches utilizing urinary microbiota data
Microbiota and Immunotherapy	Investigating the potential influence of the urinary microbiota on immunotherapeutic responses in prostate cancer.	Microbiota-based immunomodulatory approaches to enhance treatment efficacy
Long-Term Management	Exploring the role of the urinary microbiota in long-term disease management and treatment responses in prostate cancer.	Longitudinal monitoring of urinary microbiota for optimizing long-term outcomes

Management: One current topic of research is the contribution made by urinary microbiota to long-term disease management and treatment outcomes in prostate cancer. Longitudinal changes in the composition of urinary microbiota over days, weeks and months during treatment may provide clues to dynamic of disease process. - which might point to opportunities for improving long-term outcomes by adjusting course along the way (46).

7. Future Directions

In the fields of prostate cancer research and its clinical applications, there is still a vast frontier to be explored in studying the urinary microbiota. A number of promising directions are set to influence the conceptualized role-and subsequently applications in precision medicine and innovative therapeutic strategies for prostate cancer-of this evolving understanding of the urinary microbiota.

1. Microbiota-Host Interactions: With the goal of just such novel discoveries, further analysis to illuminate deeper layers--the complex relations between urinary microbiota and host immune system; interactions between the genitourinary microenvironment and tumor cells-is certain to yield much fruit.
2. Biomarker Development: A future research priority is advancing efforts to discover and confirm microbial signatures as diagnostic, prognostic, or predictive biomarkers for prostate cancer. Adding urinary microbiota data into current risk stratification models and treatment algorithms may further refine disease management.
3. Longitudinal Studies: In order to determine whether the urinary microbiota composition also changes dynamically during prostate cancer progression, treatment interventions, and long-term follow-up period we must undertake longitudinal studies.
4. Microbiota Modulation Strategies: While those approaches are still being explored, looking at advanced microbiota modulation strategies--including targeted microbial therapies, engineered microbial communities and personalized combination interventions--may provide some new ideas about changing the composition of the urinary bacteriome to modulate its effects on prostate cancer progression.

5. Clinical Translation: Another important frontier of microbial signature research is to promote the clinical translation for applications in non-invasive diagnostic and prognostic tests, as well personalized therapeutic interventions.
6. Multi-Omics Approaches: Using multi-omics approaches like metagenomics, metatranscriptomics, and both cohorts of patients with prostate cancer were analyzed sequentially. Metabolites as well as microbial proteins can be used to interpret the role that the urinary microbiome plays in prostatic carcinogenesis.
7. Therapeutic Development: Shaping personalized treatment paradigms With the development of novel therapeutic interventions that act on urinary microbiota, such as selective and representative ones like those based upon microbiome-driven immunomodulation or precision medicine approaches, innovative combinations with HMG/DA tablets are likely to enrich our armamentarium in tackling urodiatheses.

8. Conclusion

Over the course of its own evolution, urinary microbiota research has reached a new threshold at prostate cancer as our spear's tip. The shining frontier being explored for us, besides offering the hope of disease understanding and diagnostic application can perhaps anticipate also breakthroughs in therapy which will change medicine itself. Another path of person-based direction to disease prevention A more important potential biological cause of prostate cancer is the everchanging population and intricate dynamic relationship among microbes in the genitourinary system.

In addition to diagnostic tests using microbial signatures of prostate cancer, researchers are looking for factors to predict the outcome and possible targets for therapeutic intervention. Whether or not the urinary microbiota might affect disease progression, how resistant a patient is to treatment and even whether he survives offers an opportunity for exploring new paths in prostate cancer care.

In addition, there are promising prospects for further development of advanced microbiota modulation strategies as well as increased use of multi-omics approach and clinical translation efforts. Through the amalgamation of knowledge gained from microbiome research, immunotherapy and precision medicine techniques, we come to view urinary microbiota as a major influencer in our attempts at increased understanding or better management of this disease.

The urinary microbiota and the various aspects of its relevance for prostate cancer research will naturally continue to be deciphered by researchers, though as a result we are on the threshold now ready with prospects--greater even than personalized therapeutic applications such that had utopian-like visions among molecular biologists back in the 1980's; there Microbiome science, oncology and clinical practice are coming together to pave a promising course for the future of prostate cancer treatment.

In short, prostate cancer offers a rich field of possibilities for further investigation and development. With the discovery of microbial signatures in disease and with a personalized approach to treatment, researchers hope to open up new battle fronts for precision oncology and determine where prostate cancer is headed.

FUNDING

No funding received for this work

ACKNOWLEDGEMENT

The authors would like to thank the anonymous reviewers for their efforts.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCE

- [1] H. Zhang, H. Yang, S. Bandyopadhyay, M. T. Milano, C. Fung, E. M. Messing, et al., "Increased risk of high-grade prostate cancer among testicular cancer survivors," *PLoS One*, vol. 17, no. 2, p. e0263573, 2022.
- [2] E. Tvrdá, A. Agarwal, and N. Alkuhaimi, "Male Reproductive Cancers and Infertility: A Mutual Relationship," *Int. J. Mol. Sci.*, vol. 16, no. 4, pp. 7230-7260, 2015.
- [3] M. Colella, S. Topi, R. Palmirotta, D. D'Agostino, I. A. Charitos, R. Lovero, et al., "An Overview of the Microbiota of the Human Urinary Tract in Health and Disease: Current Issues and Perspectives," *Life*, vol. 13, no. 7, p. 1486, 2023.
- [4] V. Perez-Carrasco, A. Soriano-Lerma, M. Soriano, J. Gutiérrez-Fernández, and J. A. Garcia-Salcedo, "Urinary Microbiome: Yin and Yang of the Urinary Tract," *Front Cell Infect Microbiol*, vol. 11, p. 617002, 2021.

- [5] N. Kustrimovic, R. Bombelli, D. Baci, and L. Mortara, "Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment," *Int. J. Mol. Sci.*, vol. 24, no. 2, 2023.
- [6] M. S. Litwin and H. J. Tan, "The diagnosis and treatment of prostate cancer: a review," *JAMA*, vol. 317, no. 24, pp. 2532-2542, 2017.
- [7] P. Rawla, "Epidemiology of Prostate Cancer," *World J Oncol*, vol. 10, no. 2, pp. 63-89, 2019.
- [8] H. E. Taitt, "Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location," *Am J Mens Health*, vol. 12, no. 6, pp. 1807-1823, 2018.
- [9] J. L. Descotes, "Diagnosis of prostate cancer," *Asian J Urol*, vol. 6, no. 2, pp. 129-136, 2019.
- [10] S. Knipper, S. Ott, H. P. Schlemmer, M. O. Grimm, M. Graefen, and T. Wiegel, "Options for Curative Treatment of Localized Prostate Cancer," *Dtsch Arztebl Int*, vol. 118, pp. 228-236, 2021.
- [11] M. Sekhoacha, K. Riet, P. Motloung, L. Gumenuku, A. Adegoke, and S. Mashele, "Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches," *Molecules*, vol. 27, no. 17, 2022
- [12] S. Belkahla, I. Nahvi, S. Biswas, I. Nahvi, and N. Ben Amor, "Advances and development of prostate cancer, treatment, and strategies: A systemic review," *Front Cell Dev Biol*, vol. 10, p. 991330, 2022.
- [13] J. Shreffler and M. R. Huecker, "Diagnostic testing accuracy: Sensitivity, specificity, predictive values and likelihood ratios," 2020.
- [14] M. Teoh, D. Lee, D. Cooke, and M. G. Nyandoro, "Digital Rectal Examination: Perspectives on Current Attitudes, Enablers, and Barriers to Its Performance by Doctors-in-Training," *Cureus*, vol. 15, no. 6, p. e40625, 2023.
- [15] M. K. David and S. W. Leslie, "Prostate specific antigen," *StatPearls [Internet]: StatPearls Publishing*, 2022.
- [16] C. J. Harvey, J. Pilcher, J. Richenberg, U. Patel, and F. Frauscher, "Applications of transrectal ultrasound in prostate cancer," *Br J Radiol*, vol. 85, Spec Iss 1, pp. S3-S17, 2012.
- [17] I. Bhattacharya, Y. S. Khandwala, S. Vesal, W. Shao, Q. Yang, S. J. C. Soerensen, et al., "A review of artificial intelligence in prostate cancer detection on imaging," *Ther Adv Urol*, vol. 14, p. 17562872221128791, 2022.
- [18] S. F. Shariat and C. G. Roehrborn, "Using biopsy to detect prostate cancer," *Rev Urol*, vol. 10, no. 4, pp. 262-280, 2008.
- [19] S. Ju, C. Chen, J. Zhang, L. Xu, X. Zhang, Z. Li, et al., "Detection of circulating tumor cells: opportunities and challenges," *Biomark Res*, vol. 10, no. 1, p. 58, 2022.
- [20] S. Loeb and W. J. Catalona, "The Prostate Health Index: a new test for the detection of prostate cancer," *Ther Adv Urol*, vol. 6, no. 2, pp. 74-77, 2014.
- [21] S. Punnen, N. Pavan, and D. J. Parekh, "Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer," *Rev Urol*, vol. 17, no. 1, pp. 3-13, 2015.
- [22] A. Bourdounis, A. G. Papatsoris, M. Chrisofos, E. Efstathiou, A. Skolarikos, and C. Deliveliotis, "The novel prostate cancer antigen 3 (PCA3) biomarker," *Int Braz J Urol*, vol. 36, no. 6, pp. 665-668, discussion 669, 2010.
- [23] S. Ghai and M. A. Haider, "Multiparametric-MRI in diagnosis of prostate cancer," *Indian J Urol*, vol. 31, no. 3, pp. 194-201, 2015.
- [24] C. D. Davis, "The Gut Microbiome and Its Role in Obesity," *Nutr Today*, vol. 51, no. 4, pp. 167-174, 2016.
- [25] S. M. Jandhyala, R. Talukdar, C. Subramanyam, H. Vuyyuru, M. Sasikala, and D. Nageshwar Reddy, "Role of the normal gut microbiota," *World J Gastroenterol*, vol. 21, no. 29, pp. 8787-8803, 2015.
- [26] J. B. Xavier, V. B. Young, J. Skufca, F. Ginty, T. Testerman, A. T. Pearson, et al., "The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View," *Trends Cancer*, vol. 6, no. 3, pp. 192-204, 2020.
- [27] J. Kim and H. K. Lee, "Potential Role of the Gut Microbiome In Colorectal Cancer Progression," *Front Immunol*, vol. 12, p. 807648, 2021.
- [28] M. Wang, F. Yu, and P. Li, "Intratumor microbiota in cancer pathogenesis and immunity: from mechanisms of action to therapeutic opportunities," *Front Immunol*, vol. 14, p. 1269054, 2023.
- [29] J. Rajapakse, S. Khatiwada, A. C. Akon, K. L. Yu, S. Shen, and A. Zekry, "Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions," *Gut Microbes*, vol. 15, no. 2, p. 2240031, 2023.
- [30] R. Hajjo, D. A. Sabbah, and A. Q. Al Bawab, "Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers," *Diagnostics (Basel)*, vol. 12, no. 7, 2022.
- [31] K. A. Kline and A. L. Lewis, "Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract," *Microbiol Spectr*, vol. 4, no. 2, 2016.
- [32] H. W. Choi, K. W. Lee, and Y. H. Kim, "Microbiome in urological diseases: Axis crosstalk and bladder disorders," *Investig Clin Urol*, vol. 64, no. 2, pp. 126-139, 2023.

- [33] T. V. Miya, R. Marima, B. P. Damane, E. M. Ledet, and Z. Dlamini, "Dissecting Microbiome-Derived SCFAs in Prostate Cancer: Analyzing Gut Microbiota, Racial Disparities, and Epigenetic Mechanisms," *Cancers (Basel)*, vol. 15, no. 16, 2023.
- [34] H. Yu, H. Meng, F. Zhou, X. Ni, S. Shen, and U. N. Das, "Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia," *Arch Med Sci*, vol. 11, no. 2, pp. 385-394, 2015.
- [35] O. Grobeisen-Duque, C. D. Mora-Vargas, M. G. Aguilera-Arreola, and A. C. Helguera-Repetto, "Cycle Biodynamics of Women's Microbiome in the Urinary and Reproductive Systems," *Journal of Clinical Medicine*, vol. 12, no. 12, p. 4003, 2023.
- [36] G. Ploussard and A. de la Taille, "Urine biomarkers in prostate cancer," *Nat Rev Urol*, vol. 7, no. 2, pp. 101-109, 2010.
- [37] K. Garbas, P. Zapala, Ł. Zapala, and P. Radziszewski, "The Role of Microbial Factors in Prostate Cancer Development-An Up-to-Date Review," *J Clin Med*, vol. 10, no. 20, 2021.
- [38] L. Y. Zhao, J. X. Mei, G. Yu, L. Lei, W. H. Zhang, K. Liu, et al., "Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications," *Signal Transduction and Targeted Therapy*, vol. 8, no. 1, p. 201, 2023.
- [39] J. W. Yang, S. Wan, K. P. Li, S. Y. Chen, and L. Yang, "Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma," *Front Immunol*, vol. 14, p. 1188520, 2023.
- [40] Z. Medarova, S. K. Ghosh, M. Vangel, R. Drake, and A. Moore, "Risk stratification of prostate cancer patients based on EPS-urine zinc content," *Am J Cancer Res*, vol. 4, no. 4, pp. 385-393, 2014.
- [41] N. Pernigoni, C. Guo, L. Gallagher, W. Yuan, M. Colucci, M. Troiani, et al., "The potential role of the microbiota in prostate cancer pathogenesis and treatment," *Nat Rev Urol*, vol. 20, no. 12, pp. 706-718, 2023.
- [42] Ö. C. O. Umu, K. Rudi, and D. B. Diep, "Modulation of the gut microbiota by prebiotic fibres and bacteriocins," *Microb Ecol Health Dis*, vol. 28, no. 1, p. 1348886, 2017.
- [43] T. A. Ferrara, J. W. Hodge, and J. L. Gulley, "Combining radiation and immunotherapy for synergistic antitumor therapy," *Curr Opin Mol Ther*, vol. 11, no. 1, pp. 37-42, 2009.
- [44] P. Krzyszczyk, A. Acevedo, E. J. Davidoff, L. M. Timmins, I. Marrero-Berrios, M. Patel, et al., "The growing role of precision and personalized medicine for cancer treatment," *Technology (Singap World Sci)*, vol. 6, no. 3-4, pp. 79-100, 2018.
- [45] M. C. Markowski, S. A. Boorjian, J. P. Burton, N. M. Hahn, M. A. Ingersoll, S. Maleki Vareki, et al., "The Microbiome and Genitourinary Cancer: A Collaborative Review," *Eur Urol*, vol. 75, no. 4, pp. 637-646, 2019.
- [46] A. Kawalec and D. Zwolińska, "Emerging Role of Microbiome in the Prevention of Urinary Tract Infections in Children," *Int J Mol Sci*, vol. 23, no. 2, 2022.